[go: up one dir, main page]

UA92765C2 - Фармацевтическое средство для лечения уретеролитиаза - Google Patents

Фармацевтическое средство для лечения уретеролитиаза

Info

Publication number
UA92765C2
UA92765C2 UAA200808421A UAA200808421A UA92765C2 UA 92765 C2 UA92765 C2 UA 92765C2 UA A200808421 A UAA200808421 A UA A200808421A UA A200808421 A UAA200808421 A UA A200808421A UA 92765 C2 UA92765 C2 UA 92765C2
Authority
UA
Ukraine
Prior art keywords
ureterolithiasis
cyano
substituent
carbamoyl
substituted
Prior art date
Application number
UAA200808421A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мамору Кобаяси
Йоситака Томияма
Куми Кобаяси
Original Assignee
Киссеи Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Киссеи Фармасьютикал Ко., Лтд. filed Critical Киссеи Фармасьютикал Ко., Лтд.
Publication of UA92765C2 publication Critical patent/UA92765C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Данное изобретение относится к фармацевтическим композициям, которые используются для облегчения боли, вызываемой камнями в мочеточниках, как средство, способствующее выделению камней мочеточников или т.п.Заявлена фармацевтическая композиция для лечения уретеролитиаза, которая включает как активный ингредиент производное индолина, представленное общей формулой (И), или его соль. В указанной формуле R представляет собой насыщенную или ненасыщенную алифатическую ацильную группу, которая может иметь заместитель; гидроксиалкилгруппу; алифатическую ацилоксиалкилгруппу; низшую алкилгруппу, которая содержит как заместитель низшую алкоксигруппу, карбо
UAA200808421A 2005-11-24 2006-11-22 Фармацевтическое средство для лечения уретеролитиаза UA92765C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005339188 2005-11-24

Publications (1)

Publication Number Publication Date
UA92765C2 true UA92765C2 (ru) 2010-12-10

Family

ID=38067199

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200808421A UA92765C2 (ru) 2005-11-24 2006-11-22 Фармацевтическое средство для лечения уретеролитиаза

Country Status (12)

Country Link
US (2) US20090163571A1 (ru)
EP (1) EP1956001A4 (ru)
JP (1) JP4865724B2 (ru)
KR (1) KR101232425B1 (ru)
CN (1) CN101336230B (ru)
BR (1) BRPI0618996A2 (ru)
CA (1) CA2628476C (ru)
EA (1) EA016008B1 (ru)
NO (1) NO20082816L (ru)
TW (1) TW200803843A (ru)
UA (1) UA92765C2 (ru)
WO (1) WO2007060974A1 (ru)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2132254T3 (es) * 1992-09-14 1999-08-16 Forssmann Wolf Georg Prof Dr Nueva utilizacion de inhibidores de la fosfodiesterasa iv.
EP0600675B1 (en) * 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Indoline compounds for the treatment of dysuria
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
KR100554813B1 (ko) * 2001-01-02 2006-02-22 에프. 호프만-라 로슈 아게 알파 1에이/비 아드레날린성 수용체 길항제로서의퀴나졸론 유도체
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
US20040072551A1 (en) * 2002-10-10 2004-04-15 Sanford John Richard Communication device with front-end integration

Also Published As

Publication number Publication date
KR20080071603A (ko) 2008-08-04
CN101336230B (zh) 2011-11-23
JPWO2007060974A1 (ja) 2009-05-07
EA200801420A1 (ru) 2009-02-27
TW200803843A (en) 2008-01-16
BRPI0618996A2 (pt) 2011-09-20
HK1125634A1 (en) 2009-08-14
WO2007060974A1 (ja) 2007-05-31
JP4865724B2 (ja) 2012-02-01
CA2628476C (en) 2013-10-15
TWI379680B (ru) 2012-12-21
EA016008B1 (ru) 2012-01-30
EP1956001A4 (en) 2012-12-26
US20110230538A1 (en) 2011-09-22
US20090163571A1 (en) 2009-06-25
CA2628476A1 (en) 2007-05-31
EP1956001A1 (en) 2008-08-13
KR101232425B1 (ko) 2013-02-12
NO20082816L (no) 2008-08-13
CN101336230A (zh) 2008-12-31

Similar Documents

Publication Publication Date Title
EA200802329A1 (ru) Производные триазола ii
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
EA201000007A1 (ru) Производные индазоламида
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
NO20090202L (no) Prolylhydroksylaseinhibitorer
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
TW200616953A (en) Indole, indazole or indoline derivatives
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
WO2008105383A1 (ja) ピラゾール誘導体およびその医薬用途
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MXPA05010020A (es) Derivados de oxamida.
WO2003070728A3 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
UA97483C2 (ru) Производное пиримидина в качестве ингибитора pi3k и его применение
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease